COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic

May 12, 2021 updated by: Merve Firat, Hacettepe University

COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic

In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

74

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey
        • Hacettepe University, Faculty of Physical Therapy and Rehabilitation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients and healthy individuals between 18-60 years old, who are diagnosed with non-cystic fibrosis bronchiectasis, and whose local language is Turkish will be included in the study.

Description

Inclusion Criteria:

  • Having been diagnosed with non-cystic fibrosis bronchiectasis
  • No acute bronchiectasis exacerbation or infection in the past 2 weeks
  • Volunteering to participate in the research

Exclusion Criteria:

  • Having a cognitive problem
  • Not being literate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Bronchiectasis
Having been diagnosed with non-cystic fibrosis bronchiectasis
Healthy individuals
Healthy individuals without chronic disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
COVID-19 Phobia
Time Frame: 5 minutes
COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.
5 minutes
Qol
Time Frame: 10 minutes
Quality of life was evaluated with Nottingham Health Profile
10 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health anxiety
Time Frame: 10 minutes
Health anxiety was evaluated with Health Anxiety Inventory
10 minutes
Physical activity
Time Frame: 5 minutes
Physical activity level was evaluated with International Physical Activity Questionnaire - Short Form (IPAQ-SF)
5 minutes
Quality of sleep
Time Frame: 10 minutes
Quality of sleep was evaluated with Pittsburgh Sleep Quality Index
10 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hacettepe University

Investigators

  • Study Chair: Aslıhan Cakmak, MSc, Hacettepe University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 23, 2020

Primary Completion (ACTUAL)

December 18, 2020

Study Completion (ACTUAL)

January 31, 2021

Study Registration Dates

First Submitted

July 23, 2020

First Submitted That Met QC Criteria

July 23, 2020

First Posted (ACTUAL)

July 27, 2020

Study Record Updates

Last Update Posted (ACTUAL)

May 13, 2021

Last Update Submitted That Met QC Criteria

May 12, 2021

Last Verified

December 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GO 20/602

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bronchiectasis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe